Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2596 to 2610 of 8905 results

  1. Deutetrabenazine for treating tardive dyskinesia [ID6550]

    In development Reference number: GID-TA11718 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over [ID6448]

    In development Reference number: GID-TA11564 Expected publication date:  08 July 2026

    Technology appraisal guidance
    In development

  3. Cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma after surgery and radiotherapy [ID6659]

    In development Reference number: GID-TA11869 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Apadamtase alfa for treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 18 February 2026.

    Technology appraisal guidance
    In consultation

  5. Cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma after surgery and radiotherapy [ID6659]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 19 February 2026.

    Technology appraisal guidance
    In consultation

  6. Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable [ID6249]

    In development Reference number: GID-TA11254 Expected publication date:  13 May 2026

    Technology appraisal guidance
    In development

  7. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism

    In development Reference number: GID-NG10469 Expected publication date: TBC

    NICE guideline
    In development

  8. Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]

    In development Reference number: GID-TA11386 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]

    Awaiting development Reference number: GID-TA11215 Expected publication date:  07 May 2026

    Technology appraisal guidance
    Awaiting development

  10. Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]

    In development Reference number: GID-TA11091 Expected publication date:  22 April 2026

    Technology appraisal guidance
    In development

  11. Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 24 February 2026.

    Technology appraisal guidance
    In consultation

  12. Lisocabtagene maraleucel for treating relapsed or refractory mantle cell lymphoma [ID6695]

    Awaiting development Reference number: GID-TA11930 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Semaglutide 7.2 mg single-dose device for managing overweight and obesity [ID6699]

    Awaiting development Reference number: GID-TA11920 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Epcoritamab + R-CHOP for Diffuse large B-cell lymphoma [ID6701]

    Awaiting development Reference number: GID-TA11935 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. 12 SQ-HDM SLIT for treating allergic rhinitis caused by house dust mites in children 5 to 11 years [ID6510]

    In development Reference number: GID-TA11635 Expected publication date:  26 August 2026

    Technology appraisal guidance
    In development